OBI — Ondine Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- £56.64m
- £51.45m
- CA$2.05m
Annual cashflow statement for Ondine Biomedical, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2010 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.26 | -50.1 | -19.4 | -14.4 | -19.1 |
| Depreciation | |||||
| Non-Cash Items | -0.067 | 36.9 | 2.41 | 0.442 | 1.08 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.306 | 0.147 | 0.125 | -0.27 | 1.96 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -2.72 | -12.5 | -16.3 | -13.7 | -15.5 |
| Capital Expenditures | -0.18 | -0.077 | -0.311 | -0.177 | -0.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.665 | — | — | — | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0.485 | -0.077 | -0.311 | -0.177 | -0.01 |
| Financing Cash Flow Items | — | -1.17 | -0.023 | -0.7 | -1.93 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.06 | 41.9 | -0.275 | 3.79 | 21.7 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.179 | 29.2 | -16.6 | -10.1 | 6.79 |